Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

Figures & data

Table 1. Clinical features and 90 day follow-up results of verfied SARS-CoV-2 infection in patients with haematological disease.

	All patients (n = 108)	Multiple myeloma (n = 20)	Chronic lymphocytic leukaemia / lymphoma (n = 49)	Acute leukaemia / Myelodysplastic syndrome (n = 14)	Other* (n = 25)	Total missing
Fever, n (%)	73 (67.6)	13 (65.0)	33 (67.3)	10 (71.4)	17 (68.0)	0
Cough, n (%)	66 (61.1)	11 (55.0)	32 (65.3)	8 (57.1)	15 (60.0)	0
Dyspnoea, n (%)	31 (28.7)	3 (15.0)	14 (28.6)	4 (28.6)	10 (40.0)	0
Headache, n (%)	14 (13.0)	1 (5.0)	8 (16.3)	2 (14.3)	3 (12.0)	0
Myalgia, n (%)	8 (7.4)	0 (0.0)	3 (6.1)	4 (28.6)	1 (4.0)	0
Diarrhea, n (%)	8 (7.4)	1 (5.0)	6 (12.2)	1 (7.1)	0 (0.0)	0
COVID severity, n (%)						1
Mild	61 (57.0)	15 (75.0)	26 (54.2)	5 (35.7)	15 (60.0)
Severe	34 (31.8)	3 (15.0)	19 (39.6)	5 (35.7)	7 (28.0)
Critical	12 (11.2)	2 (10.0)	3 (6.2)	4 (28.6)	3 (12.0)
Hospitalised, n (%)	77 (71.3)	15 (75.0)	36 (73.5)	13 (92.9)	13 (52.0)	0
Asymptomatic, n (%)	12 (11.1)	4 (20.0)	5 (10.2)	1 (7.1)	2 (8.0)	0
Respiratory frequency / min, mean (SD)	20.9 (6.4)	19.0 (5.7)	21.5 (6.2)	19.9 (3.4)	22.1 (8.3)	17
Blood oxygen saturation < 90%, n (%)	5 (5.4)	3 (16.7)	0 (0.0)	0 (0.0)	2 (11.1)	15
X-ray/CT of thorax performed, n (%)	74 (68.5)	14 (70.0)	34 (69.4)	11 (78.6)	15 (60.0)	0
COVID-19-related pneumonia, n (%)	57 (52.8)	14 (70.0)	24 (49.0)	10 (71.4)	9 (36.0)	0
Performance status ≥ 2, n (%)	52 (50.5)	10 (50.0)	19 (40.4)	10 (76.9)	13 (56.5)	5
Site of transmission, n (%)						0
Household	10 (9.3)	2 (10.0)	7 (14.3)	1 (7.1)	0 (0.0)
Imported	6 (5.6)	2 (10.0)	2 (4.1)	0 (0.0)	2 (8.0)
Hospital	14 (13.0)	6 (30.0)	5 (10.2)	1 (7.1)	2 (8.0)
Other close contact	11 (10.2)	1 (5.0)	6 (12.2)	1 (7.1)	3 (12.0)
Unknown	67 (62.0)	9 (45.0)	29 (59.2)	11 (78.6)	18 (72.0)
Supplementary oxygen, n (%)	61 (56.5)	8 (40.0)	28 (57.1)	12 (85.7)	13 (52.0)	0
ICU, n (%)	23 (21.3)	4 (20.0)	11 (22.4)	4 (28.6)	4 (16.0)	0
CPAP / NIV, n (%)	10 (9.3)	1 (5.0)	6 (12.2)	2 (14.3)	1 (4.0)	0
Ventilator, n (%)	16 (14.8)	3 (15.0)	6 (12.2)	3 (21.4)	4 (16.0)	0
90-days survival (95% CI)	72 (64–81)	75 (58–97)	71 (60–85)	50 (30–84)	84 (71–100)	0
Re-assessed 80–120 days after infection, n (%)	49 (45.4)	10 (50.0)	25 (51.0)	4 (28.6)	10 (40.0)	0
Reductions in functional level reported after 80–120 days
More fatigued than usual, n (%)	26 (57.8)	5 (55.6)	13 (56.5)	4 (100.0)	4 (44.4)	4
More dyspnoea than usual, n (%)	20 (51.3)	5 (55.6)	9 (42.9)	2 (100.0)	4 (57.1)	10
Functional abilities reduced, n (%)	23 (54.8)	5 (62.5)	10 (45.5)	3 (100.0)	5 (55.6)	7

*Myeloproliferative neoplasms, immune thrombocytopenia, paroxysmal nocturnal haemoglobinuria, aplastic anaemia, etc.

Figure 1. Survival among Danish patients with haematological disorders after SARS-CoV-2 infection.